Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Shares experienced unusually high volume—1,032,133 shares traded on Friday (up 207% from the prior session) and the stock last traded at $40.39, well above its 50-day ($30.07) and 200-day ($28.49) moving averages.
• Analysts collectively rate the stock a consensus Buy with a consensus target price of $53.83, and multiple firms (Goldman Sachs, TD Cowen, BTIG) have recently reiterated or raised positive ratings/targets.
• Fundamentals and insider activity show caution: the company missed quarterly EPS estimates (‑$0.72 vs. ‑$0.65) and insiders have sold 52,571 shares (~$1.62M) over the past three months, though insiders still own 13.57% of the stock.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) shares saw strong trading volume on Friday . 1,032,133 shares changed hands during trading, an increase of 207% from the previous session's volume of 335,783 shares.The stock last traded at $40.39 and had previously closed at $39.54.

Analyst Ratings Changes

Several brokerages have recently commented on RAPP. The Goldman Sachs Group reissued a "buy" rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. TD Cowen reaffirmed a "buy" rating on shares of Rapport Therapeutics in a research report on Monday, March 9th. Citigroup reissued a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Finally, BTIG Research upped their target price on shares of Rapport Therapeutics to $47.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $53.83.

Rapport Therapeutics Price Performance

The company has a market capitalization of $1.90 billion, a P/E ratio of -13.88 and a beta of 1.09. The firm has a fifty day moving average price of $30.07 and a 200-day moving average price of $28.49.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.07). On average, research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.

Insider Activity at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 5,083 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $29.36, for a total transaction of $149,236.88. Following the completion of the transaction, the chief executive officer directly owned 20,729 shares of the company's stock, valued at $608,603.44. This represents a 19.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Krishnaswamy Yeleswaram sold 10,200 shares of the firm's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $35.08, for a total transaction of $357,816.00. Following the sale, the insider owned 266,651 shares of the company's stock, valued at approximately $9,354,117.08. The trade was a 3.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 52,571 shares of company stock worth $1,618,757. 13.57% of the stock is currently owned by corporate insiders.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently bought and sold shares of the company. Baker BROS. Advisors LP lifted its position in shares of Rapport Therapeutics by 181.2% during the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock valued at $45,949,000 after buying an additional 997,000 shares during the last quarter. Vestal Point Capital LP purchased a new stake in Rapport Therapeutics during the third quarter valued at about $28,215,000. Polar Capital Holdings Plc bought a new position in Rapport Therapeutics during the third quarter worth about $27,887,000. Capital International Investors boosted its position in Rapport Therapeutics by 30.7% during the third quarter. Capital International Investors now owns 3,402,529 shares of the company's stock worth $101,055,000 after purchasing an additional 800,000 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Rapport Therapeutics by 265.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 892,258 shares of the company's stock worth $26,500,000 after purchasing an additional 648,378 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.